Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial

• Main Authors: Sumantra Sarkar (Author), Chandrakant Bokade (Author), Kapil Garg (Author), Ravi Kumar (Author), Jayesh Sanmukhani (Author), Ravindra Mittal (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza Vaccine (Split virion) I.P. (TetIV), containing two strains each of influenza A and B, developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India f...